A Phase 4 interventional study of Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID and Fluticasone propionate 250 mcg BID in Asthma, sponsored by GlaxoSmithKline. Completed at 81 sites in 5 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2016-12-09.
Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 147 studies testing fluticasone in Asthma — 1 open to participants now, 4 under way, 2 of them phase 3. Fluticasone · Asthma.
Among the 147 studies testing fluticasone in Asthma, this one is the 20th largest by enrollment of the 146 interventional ones that give a count, is one of 18 that started in 2007, is one of 52 in phase 4, and was the 33rd registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →1 of the 147 studies testing fluticasone in Asthma is open now, in 1 country. Recruiting first, the newest first:
University of Wisconsin, Madison · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Fluticasone: first FDA approval 1990 (CUTIVATE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
147 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 18 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 628 is above the median of 79 across 3,346 interventional studies indexed under Asthma.
Median enrollment 100 across the 146 interventional studies. Of the 130 that completed or were terminated, 68 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
107 of 147 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,652 studies on the registry; 118 are open to participants now.
Of its 267 completed or terminated interventional studies of FDA-regulated products, 241 (90%) have results posted.
262 studies in Asthma by GlaxoSmithKline: 7 open now, 12 under way, 7 of them phase 3. Of 240 finished, 132 (55%) have results posted.
Among the 262 studies in Asthma by GlaxoSmithKline, this one is the 24th largest by enrollment of the 238 interventional ones that give a count, is one of 20 that started in 2007, is one of 53 in phase 4, and was the 46th registered.
GlaxoSmithKline’s Asthma studies by the year they started, since 1999.
2 of the studies testing fluticasone in Asthma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05757102Phase 3GlaxoSmithKlineA Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma | 2027-01-26 |
| NCT07664527University of Wisconsin, MadisonNovel Method for Removal of Orally Deposited Inhaled Fluticasone Propionate | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 147 studies testing fluticasone in Asthma, from their registry updates:
Among GlaxoSmithKline’s 262 in Asthma:
This tab as a report to print or save as PDF → With an account.
This purpose of this study is to show the superiority and long term safety and efficacy of adding a long acting beta agonist (salmeterol) to constant dose of an inhaled corticosteroid (fluticasone propionate) in symptomatic subjects with asthma. The 12-month assessment of asthma control will provide key information on the efficacy and safety of the combination therapy. The safety measure will be an assessment of adverse events
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects eligible for enrollment in the study must meet all of the following criteria:
A female is eligible to enter and participate in the study if she is:
of child-bearing potential but has a negative urinary pregnancy test at Screening (Visit 1 and when specified in Appendix 1) and agrees to take precautions (including abstinence) which are adequate to prevent pregnancy during the study.
Acceptable methods of contraception [Hatcher, 2004] are:
double barrier method: condom or occlusive cap (diaphragm or cervical/vault caps) plus spermicidal agent
Asthma is a clinical syndrome characterized by increased responsiveness of the airways to a variety of stimuli. The major symptoms of asthma are episodes of dyspnea, wheezing, and cough, which may vary from mild and almost undetectable to severe and unremitting (status asthmaticus). The primary physiological manifestation of this hyperresponsiveness is variable airway obstruction. This can take the form of spontaneous fluctuations in the severity of obstruction, substantial improvements in the severity of obstruction following bronchodilators or , or increased obstruction caused by drugs or other stimuli [American Thoracic Society, 1987].
Table 1 (ICS Dosage Table) Inhaled Corticosteroid (Dosage (mcg/day))(LowMedium) Beclomethasone dipropionate CFC (168 = 504> 504 = 840) Beclomethasone dipropionate HFA (80 = 240>240 = 640) Triamcinolone acetonide (400 = 1000>1000 = 2000) Flunisolide (500 = 1000> 1000 = 2000) Fluticasone propionate inhalation aerosol (176 = 220> 220 = 440) Fluticasone propionate inhalation powder (100 = 250> 250 = 500) Budesonide1 (200 = 600> 600 =1200) Mometasone (200 = 400> 400 = 800) Ciclesonide (80 = 160>160 = 320)
1.Respules are allowed at a dosage of 250-500mcg/day.
Table 2 (Asthma Controller Medications) Asthma Controller Medication(s) Low dose ICS + Leukotriene modifiers Low dose ICS + Theophylline products Low Dose ICS + Inhaled anticholinergics or combination products (e.g., Atrovent or Combivent) Low Dose ICS + Long acting inhaled anticholinergic (e.g. Spiriva) Low dose ICS+ long acting beta agonist or combination products containing a low dose ICS and a long-acting beta-agonists (e.g. ADVAIR™/SERETIDE™1 100/50 mcg BID or Symbicort 160/9 mcg BID (i.e 80/4.5 mcg two inhalations BID)
1.ADVAIR/SERETIDE =250/50 mcg BID or Symbicort 320/9 mcg BID (i.e 160/4.5 mcg two inhalation BID) are not permitted.
Specific information regarding warnings, precautions, , adverse events, and other pertinent information on the product that may impact subject eligibility is provided in the IB and the product labels.
Exclusion Criteria:
Subjects meeting any of the following criteria must not be enrolled in the study:
1.Life-Threatening Asthma: A subject must not have life-threatening asthma. Life-threatening asthma is defined for this protocol as a history of significant asthma episode(s) requiring intubation associated with hypercapnia, respiratory arrest, or hypoxic seizures, or asthma-related syncopal episode(s) within the 12 months prior to screening (Visit 1).
2.Worsening of Asthma: A subject must not have experienced a worsening of asthma which involved an ER visit, hospitalization or use of oral/parenteral within 4 weeks of screening (Visit 1).
3.Intermittent, Seasonal, or Exercise-Induced Asthma Alone: Subjects with only intermittent or seasonal or exercise-induced asthma are excluded from participation in this study.
4.Concurrent Respiratory Disease: A subject must not have current evidence of pneumonia, pneumothorax, atelectasis, pulmonary fibrotic disease, chronic bronchitis, emphysema, , or other respiratory abnormalities other than asthma.
5.Concurrent Conditions/Diseases: A subject with historical or current evidence of any , co-morbid or uncontrolled condition or disease state that, in the opinion of the investigator, would put the safety of the subject at risk through study participation or would confound the interpretation of the results if the condition/disease exacerbated during the study.
The list of excluded conditions/diseases includes, but is not limited to:
congestive heart failure known aortic aneurysm clinically significant coronary clinically significant cardiac arrhythmia heart disease stroke within 3 months of screening (Visit 1) uncontrolled hypertension coronary artery disease hematologic, hepatic, or renal disease cystic fibrosis poorly controlled peptic ulcer dyspnea by any other cause than asthma gastroesophageal reflux disease (GERD) not controlled by pharmacotherapy and may be causing/contributing to subject's respiratory symptoms thyrotoxicosis hypokalemia immunologic compromise current malignancy1 tuberculosis (current or quiescent) Cushing's or Addison's disease pneumonia, pneumothorax, chronic bronchitis or atelectasis uncontrolled diabetes mellitus recent history of drug or alcohol abuse 1.history of is acceptable only if subject has been in remission for one year prior to screening (Visit 1; remission = no treatment for the malignancy in the 12 months prior to screening [Visit 1])
Asthma Medications: Asthma medications listed below must not have been used prior to screening (Visit 1) for the required exclusion period as indicated below:
Medication (Exclusion Period Prior to screening (Visit 1)) Oral or parenteral systemic corticosteroids (4 weeks) Omalizumab (Xolair) (6 months)
<!-- -->
Concurrent Medications: A subject must not have the concurrent use of any of the following medications that interact with any of the study drugs used in this study, or that may affect the course of asthma or interact with sympathomimetic amines, such as:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Fluticasone propionate 250 mcg BID
Drug: Fluticasone propionate 250 mcg BID
Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID
Drug: Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID
Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID
Also known as: Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID and Fluticasone propionate 250 mcg BID
Fluticasone propionate 250 mcg BID
Mean Change From Baseline in Pre-dose FEV1 Over Weeks 1-52
Pulmonary function was measured by forced expiratory volume in one second (FEV1), which is the volume of air exhaled from the lungs in one second. Change from baseline was calculated as the average of the Week 1 through Week 52 values minus the baseline value.
Time frame: Baseline and Week 1 through Week 52
Mean Change From Baseline in AM PEF Over Weeks 1-52
Morning (AM) peak expiratory flow (PEF) is defined as the maximum volume of air exhaled in liters per minute. Change from baseline was calculated as the average of the Week 1 through Week 52 values minus the baseline value.
Time frame: Baseline and Week 1 through Week 52
Mean Change From Baseline in the Percentage of Symptom-free Days Over Weeks 1-52
A symptom-free day was defined as a day without asthma symptoms, as measured via the daily asthma symptom score (measuring symptoms during the day and previous night) on a 6-point scale (ranging from 0 to 5). A symptom score of 0=no symptoms, 1=symptoms for one short period, 2=symptoms for two or more short periods, 3=symptoms that did not affect normal daily activities, 4=symptoms that did affect normal daily activities, 5=symptoms so severe that daily activities could not be performed. Change from baseline was calculated as the average of the Week 1-Week 52 values minus the baseline value.
Time frame: Baseline and Week 1 through Week 52
Rate of Asthma Attacks Per Participant Per Year
The rate of asthma attacks was defined as the mean number of attacks per participant per year. An asthma attack was defined as a \>=20% decrease in AM PEF, a \>=70% increase in albuterol use, or the occurrence of an asthma exacerbation requiring oral steroids or hospitalization.
Time frame: Week 1 through Week 52
| Milestone | FSC DISKUS 250/50 mcg BID | FP DISKUS 250 mcg BID for 52 Weeks |
|---|---|---|
| Started | 310 | 318 |
| Completed | 231 | 234 |
| Not completed | 79 | 84 |
| Withdrew: Adverse event | 6 | 9 |
| Withdrew: Lack of efficacy | 10 | 9 |
| Withdrew: Lost to follow-up | 14 | 8 |
| Withdrew: Protocol violation | 22 | 28 |
| Withdrew: Withdrawal by subject | 18 | 21 |
| Withdrew: Other | 9 | 9 |
Pulmonary function was measured by forced expiratory volume in one second (FEV1), which is the volume of air exhaled from the lungs in one second. Change from baseline was calculated as the average of the Week 1 through Week 52 values minus the baseline value.
| Liters | FSC DISKUS 250/50 mcg BID | FP DISKUS 250 mcg BID for 52 Weeks |
|---|---|---|
| Mean Change From Baseline in Pre-dose FEV1 Over Weeks 1-52 | 0.16 ± 0.017 | 0.12 ± 0.020 |
Morning (AM) peak expiratory flow (PEF) is defined as the maximum volume of air exhaled in liters per minute. Change from baseline was calculated as the average of the Week 1 through Week 52 values minus the baseline value.
| Liters/minute (L/min) | FSC DISKUS 250/50 mcg BID | FP DISKUS 250 mcg BID for 52 Weeks |
|---|---|---|
| Mean Change From Baseline in AM PEF Over Weeks 1-52 | 27.7 ± 2.85 | 14.6 ± 2.49 |
A symptom-free day was defined as a day without asthma symptoms, as measured via the daily asthma symptom score (measuring symptoms during the day and previous night) on a 6-point scale (ranging from 0 to 5). A symptom score of 0=no symptoms, 1=symptoms for one short period, 2=symptoms for two or more short periods, 3=symptoms that did not affect normal daily activities, 4=symptoms that did affect normal daily activities, 5=symptoms so severe that daily activities could not be performed. Change from baseline was calculated as the average of the Week 1-Week 52 values minus the baseline value.
| Percentage of symptom-free days | FSC DISKUS 250/50 mcg BID | FP DISKUS 250 mcg BID for 52 Weeks |
|---|---|---|
| Mean Change From Baseline in the Percentage of Symptom-free Days Over Weeks 1-52 | 37.4 ± 2.03 | 28.9 ± 1.82 |
The rate of asthma attacks was defined as the mean number of attacks per participant per year. An asthma attack was defined as a \>=20% decrease in AM PEF, a \>=70% increase in albuterol use, or the occurrence of an asthma exacerbation requiring oral steroids or hospitalization.
| attacks per participant per year | FSC DISKUS 250/50 mcg BID | FP DISKUS 250 mcg BID for 52 Weeks |
|---|---|---|
| Rate of Asthma Attacks Per Participant Per Year | 2.63 (2.17 to 3.19) | 2.73 (2.26 to 3.31) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| FSC DISKUS 250/50 mcg BID | — | 7/310 (2.3%) | 184/310 (59.4%) |
| FP DISKUS 250 mcg BID for 52 Weeks | — | 9/318 (2.8%) | 201/318 (63.2%) |
| Event | FSC DISKUS 250/50 mcg BID | FP DISKUS 250 mcg BID for 52 Weeks |
|---|---|---|
| CholelithiasisHepatobiliary disorders | 0/310 | 2/318 |
| Cardiac deathGeneral disorders | 1/310 | 0/318 |
| Ankle fractureInjury, poisoning and procedural complications | 1/310 | 0/318 |
| Breast cancerReproductive system and breast disorders | 1/310 | 1/318 |
| AnaemiaBlood and lymphatic system disorders | 1/310 | 0/318 |
| Atrial fibrillationCardiac disorders | 1/310 | 0/318 |
| Ovarian cystReproductive system and breast disorders | 1/310 | 0/318 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 1/310 | 0/318 |
| Large intestine perforationGastrointestinal disorders | 0/310 | 1/318 |
| CholecystitisInfections and infestations | 0/310 | 1/318 |
| Event | FSC DISKUS 250/50 mcg BID | FP DISKUS 250 mcg BID for 52 Weeks |
|---|---|---|
| NasopharyngitisInfections and infestations | 54/310 | 70/318 |
| HeadacheNervous system disorders | 51/310 | 60/318 |
| Upper respiratory tract infectionInfections and infestations | 45/310 | 55/318 |
| SinusitisInfections and infestations | 33/310 | 40/318 |
| BronchitisInfections and infestations | 34/310 | 38/318 |
| Back painMusculoskeletal and connective tissue disorders | 23/310 | 24/318 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 23/310 | 19/318 |
| RhinitisInfections and infestations | 23/310 | 18/318 |
| InfluenzaInfections and infestations | 15/310 | 21/318 |
| CoughRespiratory, thoracic and mediastinal disorders | 19/310 | 18/318 |
| Age, Continuous(years) | FSC DISKUS 250/50 mcg BID | FP DISKUS 250 mcg BID for 52 Weeks | Total |
|---|---|---|---|
| Mean | 40.9 ± 15.71 | 39.6 ± 16.56 | 40.2 ± 16.15 |
| Gender(Participants) | FSC DISKUS 250/50 mcg BID | FP DISKUS 250 mcg BID for 52 Weeks | Total |
|---|---|---|---|
| Female | 186 | 181 | 367 |
| Male | 124 | 137 | 261 |
| Race/Ethnicity, Customized(participants) | FSC DISKUS 250/50 mcg BID | FP DISKUS 250 mcg BID for 52 Weeks | Total |
|---|---|---|---|
| White | 254 | 262 | 516 |
| African American | 29 | 27 | 56 |
| Asian | 20 | 25 | 45 |
| American Indian | 2 | 0 | 2 |
| Other | 5 | 4 | 9 |
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
The record gives a start of May 2007, a primary completion of Apr 2009 and a completion of Apr 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2010, 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fluticasone